Efimosfermin alfa
Highest phase reached
Phase 2
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Protein
- Drug name
- Efimosfermin alfa
- bos 580
- BOS-580
- efimosfermin alfa
- Efimosfermin alfa
- Efimosfermin Alfa
- efimosfermin alfa [INN]
- EFIMOSFERMIN ALFA [USAN]
- Efimosfermin alfa [WHO-DD]
- efimosfermin alfa inn
- efimosfermin alfa usan
- efimosfermin alfa who dd
- Fc fragment of human immunoglobulin G1 (1-227) [Homo sapiens IGHG1*03 (hinge (1-10), CH2 L<sup>14</sup>>A, L<sup>15</sup> >A (11-120), CH3 (121-226), CHS (226-227))] fused via peptide linker <sup>228</sup>GS<sup>229</sup> to human fibroblast growth factor 21 (FGF-21) fragment 33-209 [Q<sup>55</sup> >C<sup>252</sup>, R<sup>105</sup> >K<sup>302</sup>, G<sup>148</sup> >C<sup>345</sup>, K<sup>150</sup> >R<sup>347</sup>, P<sup>158</sup> >S<sup>355</sup>, S<sup>195</sup> >A<sup>392</sup>, P<sup>199</sup> >G<sup>396</sup>, G<sup>202</sup> >A<sup>399</sup>]-variant (230-406 in the current sequence); dimer (6-6', 9-9')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-DG44, glycoform alfa
- fc fragment of human immunoglobulin g1 1 227 homo sapiens ighg1 03 hinge 1 10 ch2 l sup 14 sup a l sup 15 sup a 11 120 ch3 121 226 chs 226 227 fused via peptide linker sup 228 sup gs sup 229 sup to human fibroblast growth factor 21 fgf 21 fragment 33 209 q sup 55 sup c sup 252 sup r sup 105 sup k sup 302 sup g sup 148 sup c sup 345 sup k sup 150 sup r sup 347 sup p sup 158 sup s sup 355 sup s sup 195 sup a sup 392 sup p sup 199 sup g sup 396 sup g sup 202 sup a sup 399 sup variant 230 406 in the current sequence dimer 6 6 9 9 bisdisulfide produced in chinese hamster ovary cho cells cell line cho dg44 glycoform alfa
- Immunoglobulin G1 [14-alanine,15-alanine] (human γ1-chain C region C-terminal fragment) fusion protein with peptide linker (GS) fusion protein with 5-181-fibroblast growth factor 21 [27-cysteine,120-cysteine] (human), dimer
- immunoglobulin g1 14 alanine 15 alanine human γ1 chain c region c terminal fragment fusion protein with peptide linker gs fusion protein with 5 181 fibroblast growth factor 21 27 cysteine 120 cysteine human dimer
- llf 580
- LLF-580
- llf580
- Llf580
- LLF580
- CAS registry numbers
- 2765640-39-7
- ChEMBL ID
- CHEMBL6068114
- FDA ingredient codes (UNII)
- Y114QW0F16
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Drug name stem
- ef-; -ermin
Investigated indications
- Condition
- Obesity
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001073
- Subject identifier
- D009765
- Condition identifier
- EFO_0001073
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003095
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005347
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007027
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0013209
- Highest recorded phase
- 1
Trial references
- NCT03466203
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Sequence
- Type
- Protein
- Sequence
- DKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGSDSSPLLQFGGQVRQRYLYTDDACQTEAHLEIREDGTVGGAADQSPESLLQLKALKPGVIQILGVKTSRFLCQKPDGALYGSLHFDPEACSFRELLLEDGYNVYQSEAHGLPLHLPCNRSPHRDPASRGPARFLPLPGLPPALPEPPGILAPQPPDVGSSDPLAMVGGSQARSPSYAS
- Component
- Glycosylation sites (N)
- Sequence
- 77 $ 77''
- Component
- Disulfide bridges
- Sequence
- 6-6' $ 9-9' $ 41-101 $ 41'-101' $ 147-205 $ 147'-205' $ 252-345 $ 252'-345' $ 300-318 $ 300'-318'
Related records
Trials (8)
- A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry
- A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)
- Safety Study of LLF580 in Obese Volunteers